Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...
Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...
US FDA Grants ODD to Ractigen’s siRNA Therapy RAG-21 for ALS Treatment
China-based small activating RNA (saRNA) drug developer, Ractigen Therapeutics, has announced that it has received...
UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa
Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...
Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...
BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa
China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...
GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...
Astellas Pharma’s Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter
Japan-based Astellas Pharma Inc. (TYO: 4568) has announced that its supplemental New Drug Application (sNDA)...
Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan
Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based...
MSD Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial
US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has released positive topline results from...
Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student
French pharmaceutical company Servier and the US-based Dana-Farber Cancer Institute have announced the start of...
New Horizon Health Registers Three Medical Devices in Hong Kong’s Department of Health
Hangzhou-based New Horizon Health Ltd (HKG: 6606) has announced the successful registration of three of...
NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections
The National Medical Products Administration (NMPA) has taken a significant step towards enhancing transparency in...
Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Epigenic Therapeutics Receives Approval for EPI-003 Clinical Study in New Zealand
Shanghai-based Epigenic Therapeutics, a biotechnology company specializing in the development of novel gene modulation therapies,...
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a...
Beijing Balance Medical Technology’s ePTFE Implant Accepted for NMPA Review
Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that the National Medical Products...
Betta Pharmaceuticals’ MCLA-129 Approved for Clinical Trial in Advanced Solid Tumors
China’s Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from...
Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is poised to conduct an initial public offering (IPO)...